Abstract
FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.
Keywords: Acute myeloid leukemia, FLT3, Tyrosine kinase inhibitors
Current Drug Targets
Title: Bench to Bedside Targeting of FLT3 in Acute Leukemia
Volume: 11 Issue: 7
Author(s): Keith W. Pratz and Mark J. Levis
Affiliation:
Keywords: Acute myeloid leukemia, FLT3, Tyrosine kinase inhibitors
Abstract: FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.
Export Options
About this article
Cite this article as:
W. Pratz Keith and J. Levis Mark, Bench to Bedside Targeting of FLT3 in Acute Leukemia, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320782
DOI https://dx.doi.org/10.2174/138945010791320782 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Signal Transduction Therapy: Challenges to Clinical Trial Design
Current Signal Transduction Therapy Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets Doxycycline in Mitochondrial Mediated Pathway of Apoptosis: A Systematic Review
Anti-Cancer Agents in Medicinal Chemistry The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets